Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Allisartan medoxomil/indapamide extended-release - Shenzhen Salubris Pharmaceuticals

Next Previous
X
Search
Drug Profile

Allisartan medoxomil/indapamide extended-release - Shenzhen Salubris Pharmaceuticals

Alternative Names: SAL-0108

Latest Information Update: 14 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shenzhen Salubris Pharmaceuticals
  • Class Antihypertensives; Cardiovascular therapies; Indoles; Small molecules; Sulfonamides
  • Mechanism of Action Angiotensin receptor antagonists; Thiazide-like diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypertension

Most Recent Events

  • 27 May 2022 Phase-III clinical trials in Hypertension (In volunteers) in China (PO)
  • 21 Jun 2021 Preclinical trials in Hypertension in China (PO) before June 2021
  • 21 Jun 2021 Shenzhen Salubris Pharmaceuticals (Xinlitai) receives the "Clinical Trial Approval Notice" approved and issued by the State Drug Administration, agreeing to conduct clinical trials of allisartan medoxomil and indapamide sustained-release tablets

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top